Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

A Study to Compare Pharmacokinetics and Pharmacodynamics of SAR342434 to Insulin Lispro in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Type 1 Diabetes

Interventions: Drug: Insulin Lispro
Drug: SAR342434

First Posted Date: 2014-10-23

Last Posted Date: 2014-10-23

Lead Sponsor: Sanofi

Target Recruit Count: 30

Registration Number: NCT02273258

Locations: 🇩🇪
Sanofi Administrative Office, Frankfurt, Germany

Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM

Phase 3

Completed

Conditions: Diabetes Mellitus Type 2

Interventions: Drug: Insulin glargine U300 (new formulation of insulin glargine) HOE901

First Posted Date: 2014-08-28

Last Posted Date: 2014-12-03

Lead Sponsor: Sanofi

Target Recruit Count: 40

Registration Number: NCT02227212

Locations: 🇩🇪
Investigational Site Number 276008, Berlin, Germany
🇩🇪
Investigational Site Number 276011, Augsburg, Germany
🇩🇪
Investigational Site Number 276009, Essen, Germany

and more 4 locations

TOFO Insulin Combination Trial

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: TOFOGLIFLOZIN CSG452
Drug: insulin
Drug: placebo

First Posted Date: 2014-07-25

Last Posted Date: 2017-10-11

Lead Sponsor: Sanofi

Target Recruit Count: 211

Registration Number: NCT02201004

Locations: 🇯🇵
Investigational Site Number 392-004, Koga-shi, Japan
🇯🇵
Investigational Site Number 392-016, Sendai-shi, Japan
🇯🇵
Investigational Site Number 392-007, Atsugi-shi, Japan

and more 27 locations

Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: LIXISENATIDE AVE0010
Drug: Sitagliptin
Drug: Insulin glargine HOE901

First Posted Date: 2014-07-25

Last Posted Date: 2016-10-05

Lead Sponsor: Sanofi

Target Recruit Count: 136

Registration Number: NCT02200991

Locations: 🇯🇵
Investigational Site Number 392-122, Kobe-shi, Japan
🇯🇵
Investigational Site Number 392-101, Kyoto-shi, Japan
🇯🇵
Investigational Site Number 392-119, Nerima-ku, Japan

and more 17 locations

Single Dose Clamp Study To Compare Concentration/Time Profile And Metabolic Activity Profile Of 2 New Formulations Of Insulin Glargine With Lantus

Phase 1

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: insulin glargine U100 HOE901
Drug: insulin glargine U500 HOE901
Drug: insulin glargine U200 HOE901

First Posted Date: 2014-07-25

Last Posted Date: 2014-12-24

Lead Sponsor: Sanofi

Target Recruit Count: 36

Registration Number: NCT02201199

Locations: 🇩🇪
Investigational Site Number 276001, Neuss, Germany

Evaluation of SAR408701 in Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Neoplasm Malignant

Interventions: Drug: SAR408701

First Posted Date: 2014-07-11

Last Posted Date: 2025-02-10

Lead Sponsor: Sanofi

Target Recruit Count: 254

Registration Number: NCT02187848

Locations: 🇺🇸
Dana Farber Cancer Institute- Site Number : 840005, Boston, Massachusetts, United States
🇺🇸
Yale University School of Medicine Site Number : 840002, New Haven, Connecticut, United States
🇨🇦
Investigational Site Number : 124001, Toronto, Ontario, Canada

and more 17 locations

Evaluation of Efficacy of Dellegra in Exposure Unit

Phase 4

Completed

Conditions: Rhinitis Allergic

Interventions: Drug: Fexofenadine HCl 30 mg+Pseudophedrine HCl 60 mg

First Posted Date: 2014-06-26

Last Posted Date: 2015-12-18

Lead Sponsor: Sanofi

Target Recruit Count: 24

Registration Number: NCT02175485

Locations: 🇯🇵
Investigational Site Number 392-001, Shinjuku-ku, Japan

Evaluation Of Bacillus Clausii In Treatment Of Acute Diarrhea In Latin American Children

Phase 4

Completed

Conditions: Acute Gastroenteritis

Interventions: Drug: Bacillus clausii
Drug: Oral Rehydration Therapy

First Posted Date: 2014-06-23

Last Posted Date: 2016-01-21

Lead Sponsor: Sanofi

Target Recruit Count: 629

Registration Number: NCT02169817

Locations: 🇧🇷
076003, Salvador, Brazil
🇦🇷
06, San Miguel de Tucuman, Argentina
🇧🇷
076002, Curitiba, Brazil

and more 8 locations

Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Dupilumab

First Posted Date: 2014-05-08

Last Posted Date: 2022-03-28

Lead Sponsor: Sanofi

Target Recruit Count: 2282

Registration Number: NCT02134028

Locations: 🇺🇸
Investigational Site Number 840402, Tucson, Arizona, United States
🇺🇸
Investigational Site Number 840045, Long Beach, California, United States
🇺🇸
Investigational Site Number 840044, Newport Beach, California, United States

and more 362 locations

To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: sarilumab SAR153191 (REGN88)

First Posted Date: 2014-04-23

Last Posted Date: 2017-06-20

Lead Sponsor: Sanofi

Target Recruit Count: 132

Registration Number: NCT02121210

Locations: 🇷🇺
Investigational Site Number 643016, Ryazan, Russian Federation
🇵🇱
Investigational Site Number 616031, Warszawa, Poland
🇷🇺
Investigational Site Number 643006, Kemerovo, Russian Federation

and more 25 locations

Home Terms & Conditions Privacy Policy